163 related articles for article (PubMed ID: 36067206)
1. NMR-based metabolomic analysis identifies RON-DEK-β-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival.
Vicente-Muñoz S; Hunt BG; Lange TE; Wells SI; Waltz SE
PLoS One; 2022; 17(9):e0274128. PubMed ID: 36067206
[TBL] [Abstract][Full Text] [Related]
2. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
[TBL] [Abstract][Full Text] [Related]
3. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
4. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis.
Matrka MC; Watanabe M; Muraleedharan R; Lambert PF; Lane AN; Romick-Rosendale LE; Wells SI
PLoS One; 2017; 12(5):e0177952. PubMed ID: 28558019
[TBL] [Abstract][Full Text] [Related]
6. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
7. High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.
Lee SY; Jung W; Lee J; Kim A; Kim HK; Kim BH
Histol Histopathol; 2019 Nov; 34(11):1279-1288. PubMed ID: 31066459
[TBL] [Abstract][Full Text] [Related]
8. The unique DEK oncoprotein in women's health: A potential novel biomarker.
de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
[TBL] [Abstract][Full Text] [Related]
9. CD36 upregulates DEK transcription and promotes cell migration and invasion via GSK-3β/β-catenin-mediated epithelial-to-mesenchymal transition in gastric cancer.
Wang J; Wen T; Li Z; Che X; Gong L; Jiao Z; Qu X; Liu Y
Aging (Albany NY); 2020 Nov; 13(2):1883-1897. PubMed ID: 33232276
[TBL] [Abstract][Full Text] [Related]
10. DEK promotes the proliferation and invasion of lung cancers and indicates poor prognosis in lung adenocarcinomas.
Yang MQ; Bai LL; Lei L; Zheng YW; Wang Z; Li ZH; Liu CC; Huang WJ; Xu HT
Oncol Rep; 2020 Apr; 43(4):1338-1348. PubMed ID: 32020224
[TBL] [Abstract][Full Text] [Related]
11. Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma.
Yu L; Huang X; Zhang W; Zhao H; Wu G; Lv F; Shi L; Teng Y
Oncotarget; 2016 May; 7(18):26844-55. PubMed ID: 27057626
[TBL] [Abstract][Full Text] [Related]
12. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
[TBL] [Abstract][Full Text] [Related]
13. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract][Full Text] [Related]
14. Imaging-based study demonstrates how the DEK nanoscale distribution differentially correlates with epigenetic marks in a breast cancer model.
Pierzynska-Mach A; Cainero I; Oneto M; Ferrando-May E; Lanzanò L; Diaspro A
Sci Rep; 2023 Aug; 13(1):12749. PubMed ID: 37550322
[TBL] [Abstract][Full Text] [Related]
15. Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells.
Yang YS; Jia XZ; Lu QY; Cai SL; Huang XT; Yang SH; Wood C; Wang YH; Zhou JJ; Chen YD; Yang JS; Yang WJ
Oncogene; 2022 Apr; 41(18):2624-2637. PubMed ID: 35351996
[TBL] [Abstract][Full Text] [Related]
16. miR-181-5p attenuates neutrophilic inflammation in asthma by targeting DEK.
Song Y; Wang Z; Jiang J; Piao Y; Bai Q; Piao Q; Li L; Xu C; Liu H; Piao H; Li L; Yan G
Int Immunopharmacol; 2022 Nov; 112():109243. PubMed ID: 36115279
[TBL] [Abstract][Full Text] [Related]
17. DEK: A novel early screening and prognostic marker for breast cancer.
Ying G; Wu Y
Mol Med Rep; 2015 Nov; 12(5):7491-5. PubMed ID: 26459608
[TBL] [Abstract][Full Text] [Related]
18. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity.
Johnson AL; Zinser GM; Waltz SE
Oncotarget; 2015 Jun; 6(18):16304-20. PubMed ID: 26008979
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.
Wise-Draper TM; Mintz-Cole RA; Morris TA; Simpson DS; Wikenheiser-Brokamp KA; Currier MA; Cripe TP; Grosveld GC; Wells SI
Cancer Res; 2009 Mar; 69(5):1792-9. PubMed ID: 19223548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
